Impact of genetic polymorphisms on heart failure prognosis

Archives des Maladies du Coeur et des Vaisseaux

Volumn 96, Issue 3, 2003, Pages 197-206

  Le Corvoisier, P ^b   Park, H Y ^b   Carlson, K M ^b   Donahue, M P ^b   Marchuk, D A ^b   Rockman, H A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; ALDOSTERONE SYNTHASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALSEQUESTRIN; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; ENDOTHELIN A RECEPTOR;

ARTICLE; CHROMOSOME 2; CHROMOSOME 3; CROSSING OVER; DNA SEQUENCE; GENE FREQUENCY; GENE MAPPING; GENETIC POLYMORPHISM; HEART FAILURE; HUMAN; INBRED STRAIN; NONHUMAN; PHENOTYPE; PROGNOSIS; QUANTITATIVE TRAIT LOCUS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ALDOSTERONE SYNTHASE; AMP DEAMINASE; ANIMALS; CHROMOSOME MAPPING; HEART FAILURE, CONGESTIVE; HUMANS; MICE; MODELS, ANIMAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ENDOTHELIN;

EID: 0038029754     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Macintyre K, Capewell S, Stewart S et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126-31.
2. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 2002; 17: 242-52.
3. Charron P, Komajda M. Are we ready for pharmacogenomics in heart failure? Eur J Pharmacol 2001; 417: 1-9.
4. Kamisago M, Sharma SD, DePalma SR et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688-96.
5. Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics 2000; 1: 73-94.
6. Cambien F, Poirier O, Nicaud V et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet 1999; 65: 183-91.
7. Pusch W, Wurmbach JH, Thiele H, Kostrzewa M. MALDI-TOF mass spectrometry-based SNP genotyping. Pharmacogenomics 2002; 3: 537-48.
8. Rockman HA, Koch WJ Lefkowitz RJ. Seven transmembranespanning receptors and heart function. Nature 2002; 415: 206-12.
9. 1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21: 1853-8.
10. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277: 30429-35.
11. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-60.
12. 1-adrenergic receptor gene (-93C>T, -210C>T, and -2146T>C): -2146C homozygotes present in patients with idiopathic dilated cardiomyopathy and coronary heart disease. Hum Mutat 2000; 16: 534.
13. 1adrenergic receptor. J Biol Chem 1999; 274: 12670-4.
14. 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 1999; 31: 1025-32.
15. 1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 2002; 66: 723-8.
16. 2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-42.
17. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97: 10483-8.
18. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268: 23116-21.
19. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 1996; 93: 10483-8.
20. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-9.
21. 2adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86: 834-40.
22. 2-?drenoceptors. Circulation 2001; 103: 1048-50.
23. 2-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation 2000; 101: 408-14.
24. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting or half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
25. Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest 2001; 31: 476-88.
26. Raynolds MV, Bristow MR, Bush EW et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-5.
27. Andersson B, Sylven C. The DD genotype of the angiotensinconverting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28: 162-7.
28. Montgomery HE, Keeling PJ, Goldman JH, Humphries SE, Talmud PJ, Mckenna WJ. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 25: 1627-31.
29. Vancura V, Hubacek J, Malek I et al. Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy? Am J Cardiol 1999; 83: 461-2, A10.
30. McNamara DM, Holubkov R, Janosko K et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensinconverting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103: 1644-8.
31. Andersson B, Blange I, Sylven C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1999; 1: 363-9.
32. Charron P, Tesson F, Poirier O et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999; 20: 1587-91.
33. Herrmann S, Schmidt-Petersen K, Pfeifer J et al. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2001; 22: 1948-53.
34. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Camman variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999; 99: 1422-5.
35. Anderson JL, Habashi J, Carlquist JF et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000; 36: 1248-52.
36. Kupari M, Hautanen A, Lankinen L et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998; 97: 569-75.
37. Tiago AD, Badenhorst D, Skudicky D et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002; 54: 584-9.
38. Kubota T, McNamara DM, Wang JJ et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998; 97: 2499-501.
39. Dempsey AA, Dzau VJ, Liew CC. Cardiovascular genomics: estimating the total number of genes expressed in the human cardiovascular system. J Mol Cell Cardiol 2001; 33: 1879-86.
40. Suzuki M, Carlson KM, Marchuk DA, Rockman HA. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation 2002; 105: 1824-9.
41. Deschepper CF, Masciotra S, Zahabi A, Boutin-Ganache I, Picard S, Reudelhuber TL. Functional alterations of the Nppa promoter are linked to cardiac ventricular hypertrophy in WKY/WKHA rat crosses. Circ Res 2001; 88: 223-8.
42. Maltais LJ, Blake JA, Chu T, Lutz CM, Eppig JT, Jackson I. Rules and guidelines for mouse gene, allele, and mutation nomencloture: a condensed version. Genomics 2002; 79: 471-4.
43. Storer JB. Longevity and gross pathology at death in 22 inbred mouse strains. J Gerontol 1966; 21: 404-9.
44. Semsarian C, Healey MJ, Fatkin D et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33: 2055-60.
45. Boyd Y. Genetic mapping of the mouse genome. Methods 1998; 14: 120-34.
46. Dietrich WF, Miller J, Steen R et al. A comprehensive genetic map of the mouse genome. Nature 1996; 380: 149-52.
47. Lander ES, Botstein D. Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989; 121: 185-199.
48. Darvasi A, Weinreb A, Minke V, Weller JI, Soller M. Detecting marker-QTL linkage and estimating QTL gene effect and map location using a saturated genetic map. Genetics. 1993; 134: 943-51.
49. Rozmahel R, Wilschanski M, Matin A et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996; 12: 280-7.
50. Ikeda A, Zheng QY, Zuberi AR, Johnson KR, Naggert JK, Nishina PM. Microtubule-associated protein 1A is a modifier of tubby hearing (moth1). Nat Genet 2002; 30: 401-5.
51. Shah AS, White DC, Emani S et al. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-6.
52. Cho MC, Rapacciuolo A, Koch WJ, Kobayashi Y, Jones LR, Rockman HA. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 1999; 274: 22251-6.
53. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac β ARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A 2001; 98: 5809-14.
54. Flint J, Mott R. Finding the molecular basis of quantitative traits: successes and pitfalls. Nat Rev Genet 2001; 2: 437-445.
55. Boehm T. Positional cloning and gene identification. Methods 1998; 14: 152-8.
56. Swynghedauw B. Susceptibility-conferring polymorphic genotypes in cardiovascular multifactorial syndromes. Eur Heart J 2002; 23: 271-3.
57. Nadeau JH, Frankel WN. The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs. Nat Genet 2000; 25: 381-4.
58. Nadeau JH, Singer JB, Matin A, Lander ES. Analysing complex genetic traits with chromosome substitution strains. Nat Genet 2000; 24: 221-5.